Assessment of COVID-19 impact on the course of pulmonary tuberculosis E. Shishkina (Moscow, Russian Federation), L. Ergeshova (Moscow, Russian Federation), A. Egorova (Moscow, Russian Federation), N. Evseeva (Moscow, Russian Federation), T. Smirnova (Moscow, Russian Federation), N. Karpina (Moscow, Russian Federation)
Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Shishkina (Moscow, Russian Federation), L. Ergeshova (Moscow, Russian Federation), A. Egorova (Moscow, Russian Federation), N. Evseeva (Moscow, Russian Federation), T. Smirnova (Moscow, Russian Federation), N. Karpina (Moscow, Russian Federation). Assessment of COVID-19 impact on the course of pulmonary tuberculosis. 1020
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Impact of pulmonary tuberculosis on COPD outcomes Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease Year: 2021
Impact of mono- and poli-resistance on the treatment outcomes of pulmonary tuberculosis Source: International Congress 2017 – MDRTB: detection and management Year: 2017
Economic impact of pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 472s Year: 2004
Assessment of the prevalence of pulmonary involvement in cases with extrapulmonary tuberculosis Source: Annual Congress 2011 - Pulmonary and extrapulmonary tuberculosis Year: 2011
The impact of first symptoms on patient delay in pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 380s Year: 2006
Treatment outcomes of pulmonary tuberculosis cases in Izmit/Turkey Source: Eur Respir J 2004; 24: Suppl. 48, 651s Year: 2004
Influence of pulmonary tuberculosis on the quality of life of the patients Source: Eur Respir J 2005; 26: Suppl. 49, 420s Year: 2005
Effects of complex treatment with izofon of a pulmonary tuberculosis in children Source: Eur Respir J 2004; 24: Suppl. 48, 652s Year: 2004
Asthma as a sequelae to pulmonary tuberculosis Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017
Evaluating the nutritional status in active pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 427s Year: 2005
Aspects of diagnosis and treatment in pulmonary tuberculosis in children Source: Eur Respir J 2002; 20: Suppl. 38, 168s Year: 2002
Impact of pulmonary tuberculosis sequelae on functional status Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016
Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease Source: Eur Respir J, 51 (1) 1701578; 10.1183/13993003.01578-2017 Year: 2018
Causes of delay in the diagnosis of pulmonary tuberculosis Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011
The course of pulmonary TB in children with COVID-19 Source: Virtual Congress 2021 – Acute paediatric respiratory infections Year: 2021
Impact of pulmonary tuberculosis infection on chronic obstructive pulmonary disease Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases Year: 2011
Pulmonary function following treatment for pulmonary tuberculosis Source: Annual Congress 2006 - Epidemiology and control of tuberculosis Year: 2006
Clinical profile and outcome of complicated pulmonary tuberculosis in children Source: Eur Respir J 2002; 20: Suppl. 38, 362s Year: 2002
Dynamics of γ-interferon in pulmonary tuberculosis in children - in the course of chemotherapy using isofon Source: Eur Respir J 2005; 26: Suppl. 49, 655s Year: 2005
Atypical aspects of pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 507s Year: 2006